ABOUT US

We are Changing the Drug Discovery Paradigm

Congruence Therapeutics is a drug discovery company harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry.

We have a uniquely qualified team, founded by serial life sciences entrepreneur Clarissa Desjardins, PhD, most recently the founder and CEO of rare disease company Clementia Pharmaceuticals (Nasdaq: CMTA) sold to Ipsen for US$1.31 billion in 2019.  Learn more about our outstanding team below.

Leadership

Clarissa Desjardins,
Ph.D.
Chief Executive Officer
Charles Grubsztajn,
BCL, MBA
Chief Operating Officer
Sharath Hegde,
Ph.D.
Chief Scientific Officer
Tanya E. Borsuk,
Ph.D.
EVP Corporate and Business Development
Maximilian Ebert,
Ph.D.
Director of Computational Molecular Sciences
Lee D. Fader,
Ph.D.
Vice President Chemistry
Michael Rock Goldsmith, Ph.D.
Chief Innovation Officer
Jean-François Marquis,
Ph.D.
Vice President Discovery Research
Myriam Taillefer,
CPA
Vice President of Finance

Board of Directors & Observers

Nancy Harrison
Daniel Hétu
Nathaniel David
David Bonita
Didier Leconte
Alex Munn
Investors

In December 2021, we completed a Series A financing of US$50 million with top U.S. and Canadian investors, including OrbiMed, Amplitude Ventures, and Driehaus.